Therapeutic Areas
Antiplatelet Market
Biology
In the seven years that Gillian has worked at Portola, she has focused her efforts on the Company’s pipeline products...
Learn MorePortola is developing compounds to address the global epidemic of thrombosis. Currently, 110 million patients are at risk for thrombosis worldwide. By the year 2020, sales of antithrombotic drugs are expected to exceed $30 billion. Portola is developing highly differentiated products that could improve upon and potentially replace existing standard anticoagulant treatments, including Plavix® (clopidogrel).
Worldwide sales for antiplatelet drugs in 2009 exceeded $9 billion and were driven by Plavix, an irreversible oral agent with certain limitations. These include slow onset of action, variable response across patients (with up to 40 percent classified as “non-responders”), intermediate levels of maximum anti-platelet effect and increased risk of bleeding. The antiplatelet market could exceed $14 billion by 2020.